Describe USPSTF guidelines for using low-dose aspirin in pregnant women to prevent preeclampsia: when to initiate?

Describe USPSTF guidelines for using low-dose aspirin in pregnant women to prevent preeclampsia: when to initiate?

• A. After 12 weeks of gestation in women at high risk for preeclampsia
• B. Before 12 weeks of gestation in all pregnant women
• C. After 28 weeks of gestation in all pregnant women
• D. Only postpartum aspirin trials are recommended

Answer: (A)

The timing being tested is when to start low‑dose aspirin for preventing preeclampsia. The guideline recommends beginning a daily low-dose aspirin (commonly 81 mg) after 12 weeks of gestation in women who are at high risk for preeclampsia, with the goal of reducing the chance of developing the condition and related adverse outcomes. This window aligns with placentation processes early in pregnancy, where aspirin’s antiplatelet and anti-inflammatory effects can help improve placental development and blood flow. High-risk groups include women with a history of preeclampsia, multifetal pregnancy, chronic hypertension, diabetes, kidney disease, autoimmune diseases such as systemic lupus erythematosus or antiphospholipid syndrome, and other significant risk factors. The point is not to give aspirin to all pregnant individuals, but to target those at higher risk within the recommended early-to-mid second trimester window. Starting before 12 weeks hasn’t shown consistent benefit in the general population, and starting after the late second trimester misses a key window for impacting placental development, so the initiation is specifically after 12 weeks in those at high risk.

The timing being tested is when to start low‑dose aspirin for preventing preeclampsia. The guideline recommends beginning a daily low-dose aspirin (commonly 81 mg) after 12 weeks of gestation in women who are at high risk for preeclampsia, with the goal of reducing the chance of developing the condition and related adverse outcomes. This window aligns with placentation processes early in pregnancy, where aspirin’s antiplatelet and anti-inflammatory effects can help improve placental development and blood flow.

High-risk groups include women with a history of preeclampsia, multifetal pregnancy, chronic hypertension, diabetes, kidney disease, autoimmune diseases such as systemic lupus erythematosus or antiphospholipid syndrome, and other significant risk factors. The point is not to give aspirin to all pregnant individuals, but to target those at higher risk within the recommended early-to-mid second trimester window. Starting before 12 weeks hasn’t shown consistent benefit in the general population, and starting after the late second trimester misses a key window for impacting placental development, so the initiation is specifically after 12 weeks in those at high risk.